The Due Diligence Question Every Healthcare Investor Should Be Asking — But Isn't

By Ali Alqeisi | Strategic Partnerships, Marketing & Communications Manager, Emerging Health International

Healthcare private equity did not just recover in 2025. According to Cherry Bekaert’s Private Equity Report, it hit a new gear.

Capital is flowing back into the sector with renewed confidence. Healthcare ETFs experienced their largest monthly global inflows in five years in November 2025, attracting US$6.8 billion in a single month. Institutional investors who spent 2024 on the sidelines are re-entering. Deal activity is accelerating. The fundamentals — aging populations, rising chronic disease burden, expanding insurance coverage in emerging markets — remain as compelling as ever.

And yet.

The question that determines whether any of this capital generates real returns is still being asked too late, too superficially, or not at all.

It is not: Is the market large enough?

It is not: Is the financial model sound?

It is not: Does the management team have healthcare experience?

It is this:

Do the operational systems exist to make this investment perform?

Why This Question Gets Skipped

Due diligence in healthcare investment has expanded significantly over the past decade. What was once primarily financial verification has grown — as the Healthcare Due Diligence Service Market reflects, growing from USD 405.90 million in 2025 to USD 427.58 million in 2026 — to encompass clinical integrity, regulatory accountability, technology resilience, and organizational readiness.

That is genuine progress.

But there is a category of risk that remains systematically underassessed — particularly in emerging market healthcare investments. It is not the risk of a bad market. It is not the risk of poor management intent. It is the risk of an organization that cannot execute.

Not won’t. Cannot.

The distinction matters. Most healthcare investment failures in emerging markets are not caused by fraud, mismanagement, or market collapse. They are caused by the absence of the operational infrastructure required to translate a sound investment thesis into a functioning healthcare system.

Private equity investors in 2026 are placing heavier emphasis on governance systems, compliance frameworks, and risk mitigation protocols. But the emphasis is typically placed on regulatory compliance — not on the operational systems that determine day-to-day clinical and financial performance.

Those are different things. And the gap between them is where value quietly disappears.

The Execution Infrastructure Question

When an investor assesses a healthcare asset in an emerging market, the standard due diligence checklist covers the expected ground: financial statements, market analysis, competitive positioning, management credentials, regulatory standing, and exit comparables.

What it rarely covers in adequate depth is what we call execution infrastructure — the operational systems that determine whether the asset can actually perform at the level the investment thesis assumes.

Execution infrastructure includes:

Clinical governance frameworks. Are there standardized care pathways? Is there a clinical accountability structure? Is quality measured, reviewed, and acted upon systematically — or does it depend on the personal judgment of a few senior clinicians?

Workforce capability systems. Is the workforce being developed or merely deployed? Is there a leadership pipeline? What happens to performance when a key clinical leader leaves?

Operational design. Does patient flow work? Are the processes that connect admission to discharge designed and managed — or improvised daily?

Data and performance management. Is there meaningful data about operational performance? Is it used to make decisions? Or does it sit in dashboards that no one looks at?

Implementation track record. Has the organization successfully executed change before? Not planned it. Not piloted it. Executed it — at scale, sustained over time.

These questions are not exotic. They are the operational fundamentals that determine whether an investment performs or disappoints.

And in emerging market healthcare, where the supporting infrastructure that high-income markets take for granted — regulatory bodies, professional associations, workforce supply chains, quality monitoring systems — is often partial or absent, these questions are not optional.

They are the difference between a sound investment and an expensive lesson.

What the Market Is Actually Rewarding

The most sophisticated investors in 2026 have already absorbed this lesson.

PitchBook’s Q2 2025 MedTech VC Trends report found that investors are increasingly prioritizing mature platforms with scalable models — with strong emphasis on interoperability and payer alignment in deal due diligence. Scalability, in particular, has become a core diligence criterion: investors now want proof that a model can move through real-world use, not just theoretical deployment.

In private equity specifically, strong infrastructure is signaling institutional readiness — a key due diligence criterion in PE transactions. Investors are placing heavier emphasis on governance systems, compliance frameworks, and risk mitigation protocols long before closing.

The language is changing. The underlying insight is consistent: the market is beginning to price execution capability — not just market opportunity.

In emerging market healthcare, this shift is even more consequential. Because the execution gap between a promising asset and a performing one is wider here than anywhere else. The tailwinds are real. The operational complexity is also real. And the investors who treat them with equal seriousness are the ones generating returns that match the opportunity.

Three Diligence Questions That Change the Conversation

Based on the patterns EHI observes across emerging market healthcare engagements, three questions consistently expose the execution risk that standard due diligence misses:

Question 1: What happens to performance when your three best people leave?

This is not a hypothetical. It is a test of system design. In high-performing organizations, the answer is: performance is maintained, because systems carry the organization, not individuals. In most emerging market healthcare assets, the honest answer reveals a fragile dependency on a small number of indispensable people — and a complete absence of the governance and process infrastructure that makes performance sustainable.

Question 2: Show me the last three quality improvement initiatives. What changed, and how do you know?

This question tests two things simultaneously: whether the organization has a functioning quality management system, and whether it has a culture of honest performance assessment. Investors who ask this question typically discover one of two things — either a robust answer that signals genuine operational maturity, or a vague response that reveals the quality function exists on paper but not in practice.

Question 3: Walk me through how a patient moves through your facility from admission to discharge.

This is the single most revealing operational question in healthcare due diligence. A confident, specific answer — with clear ownership at each stage, standardized pathways, and defined escalation procedures — signals an operationally mature organization. Hesitation, inconsistency, or a generic response signals operational ambiguity that will translate directly into financial underperformance.

These questions do not require clinical expertise to ask. They require the conviction that execution infrastructure is as investable — and as diligence-worthy — as financial structure.

The Partner Question

No amount of rigorous due diligence eliminates execution risk in emerging market healthcare. What it does is make it visible — and therefore manageable.

But identifying execution gaps is only half the work. The other half is having a partner with the capability to close them.

Healthcare spending reached an estimated $11.3 trillion globally in 2025, with projected annual growth of 5.2% through 2030. Investors with emerging market exposure are sitting on an enormous opportunity. The question is not whether the opportunity is real.

The question is: who is going to build the operational infrastructure that allows the opportunity to generate the returns it promises?

The answer to that question — not the market analysis, not the financial model, not the management presentation — is the most important due diligence finding any investor in emerging market healthcare can produce.

Because the execution gap is not a market problem. It is an implementation problem.

And implementation problems require implementation partners — not just investment capital.

References

Cherry Bekaert (2026). Private Equity Report: 2025 Trends and 2026 Outlook. https://www.cbh.com/insights/reports/private-equity-report-2025-trends-and-2026-outlook/
BlackRock / iShares (2026). Healthcare Making a Comeback? https://www.blackrock.com/au/insights/ishares/2026-comeback-year-for-healthcare
Research and Markets (2026). Healthcare Due Diligence Service Market — Global Forecast 2026-2032. https://www.researchandmarkets.com/reports/6122505/healthcare-due-diligence-service-market-global
The Bloom Organization (2026). Private Equity Trends Shaping Healthcare Deals in 2026. https://bloomllc.com/private-equity-trends-shaping-healthcare-deals-in-2026/
HTD Health (2026). MedTech Investment Trends & Predictions for 2026. https://htdhealth.com/insights/medtech-investment-trends-predictions-for-2026/
PwC (2026). Health Services: US Deals 2026 Outlook. https://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.html
OECD (2026). Global Healthcare Spending Briefing 2026. Referenced in Healthcare Investment Trends 2026.

Ali Alqeisi is Strategic Partnerships, Marketing & Communications Manager at Emerging Health International — a healthcare transformation partner working across emerging markets to bridge the gap between strategy and real-world implementation.

For more insights on healthcare transformation in emerging markets, explore our Insights section or read our previous articles: